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Abstract: Dermatitis herpetiformis (DH), a cutaneous manifestation of coeliac disease, is characterized
by transglutaminase (TG) 3-targeted dermal immunoglobulin A (IgA) deposits. The treatment for
DH is the same as for coeliac disease, namely a life-long gluten-free diet. DH patients typically
have gluten-dependent circulating autoantibodies targeting TG3 and TG2, and plasma cells secreting
such autoantibodies have been detected in the small intestinal mucosa. This study investigates the
gluten-responsiveness of intestinal TG3 and TG2 antibody-secreting plasma cells in 16 treated DH
patients undergoing a gluten challenge. The frequency of both plasma cell populations increased
significantly during the challenge, and their frequency correlated with the corresponding serum
autoantibody levels at post-challenge. TG3-specific plasma cells were absent in all 18 untreated
coeliac disease patients and seven non-coeliac control subjects on gluten-containing diets. These
findings indicate that, in DH, both intestinal TG3- and TG2-antibody secreting plasma cells are
gluten-dependent, and that TG3-antibody secreting plasma cells are DH-specific.
Keywords: coeliac disease; dermatitis herpetiformis; transglutaminase; autoantibody; plasma cell
1. Introduction
Dermatitis herpetiformis (DH), a cutaneous manifestation of coeliac disease, is characterised by
an itching and blistering rash predominantly on the elbows, knees, and buttocks that arises in response
to the ingestion of gluten-containing cereals, i.e., wheat, rye, and barley. The key diagnostic feature
for DH is the presence of granular immunoglobulin A (IgA) deposits in the papillary dermis, which
are known to target an endogenous human protein, transglutaminase (TG) 3 [1]. Furthermore, in the
majority of DH patients, IgA-class anti-TG3 autoantibodies are also found in the circulation [1,2]. The
circulating TG3 autoantibodies are not entirely specific to DH, as approximately 30% of untreated
coeliac patients have elevated levels of these autoantibodies in the absence of any skin symptoms [3,4].
In DH patients, the skin symptoms slowly resolve during a gluten-free diet, the well-accepted and
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eective treatment, but the disappearance of TG3-targeted IgA deposits from the skin takes many
years despite the faster clearance of the serum TG3 autoantibodies [1,5–9].
As DH and coeliac disease are dierent manifestations of the same condition, they also share the
major genetic susceptibility conferred by HLA-DQ2 or -DQ8 [10]. In addition, small bowel mucosal
villous atrophy [11,12] or at least coeliac-type inflammatory changes are typically present also in
untreated DH [13,14]. The major autoantigen in coeliac disease is TG2, a member of the TG family
along with TG3, and untreated patients characteristically have TG2-targeting autoantibodies (e.g., TG2
and endomysial antibodies, EmA) in the circulation and within various tissues, including the small
intestine; as deposits at the subepithelial basement membrane and around the blood vessels [15,16].
Gluten-dependent TG2 autoantibodies are commonly found also in DH both in the serum and in the
small intestinal mucosa [17,18]. In untreated coeliac disease, TG2 antibody-secreting plasma cells are
present in the small bowel at a high frequency, and their number decreases on a gluten-free diet [19–21].
We have recently established that TG3 antibody-secreting cells are present in the small bowel mucosa
in DH [22], but no other studies have addressed intestinal TG3 or TG2 plasma cells in DH. Therefore,
we investigated the frequency and gluten-responsiveness of both of these plasma cell populations in
treated DH patients undergoing a gluten challenge, assessed their correlations with corresponding
serum antibodies, and compared their presence in DH and coeliac disease.
2. Materials and Methods
2.1. Patients
The DH patient cohort included 11 males and 5 females, who were recruited on voluntary basis
to a prospective gluten challenge study to investigate the possible development of gluten tolerance
as described elsewhere [9]. At the time of recruitment, the patients were adhering to a gluten-free
diet. In all patients, the DH diagnosis had been based on the typical clinical picture and the presence
of granular IgA deposits in the papillary dermis as demonstrated with a direct immunofluorescence
examination. At pre-challenge, the median age of the patients was 58 (range 37–72) years, and the
patients had been on gluten-free diet for a median of 22 (range 5–40) years (Table 1). The inclusion
criteria for the gluten challenge were clinical remission for at least three years, negativity for TG2
antibodies and EmA, and normal villous architecture in a duodenal biopsy. The gluten challenge
comprised an initial three-day challenge with 200 g of commercially available wheat-based bread
(equivalent to 10 slices) daily followed by a gluten-containing diet with a minimum of 10 g of wheat
per day. Post-challenge examinations were performed upon the appearance of a DH rash or positive
seroconversion (either TG2 antibodies or EmA), or after 12 months of the gluten challenge. Pre- and
post-challenge investigations included skin and small intestinal biopsies as well as the determination
of TG2 and TG3 antibodies and EmA in the patient’s serum.
Table 1. Demographic data of patients participating the study.
Dermatitis
Herpetiformis n = 16
Coeliac Disease
Non-Coeliac
Controls n = 7Untreated Treated
n = 18 n = 15
Females; n (%) 5 (31) 11 (61) 11 (73) 6 (86)
Age, years, median (range) 58 (37–72) 50 (18–71) 48 (19–72) 47 (24–76)
Duration of GFD at diagnosis,
years, median (range) 22 (5–40) 0 1 (1–1) 0
GFD: gluten-free diet.
The coeliac disease control group consisted of both untreated (n = 18) and treated (n = 15) patients
having adhered to a gluten-free diet for one year (Table 1). The median age of the untreated patients
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was 50 (range 18–71) years; seven were male and 11 were female. The median villous height crypt
depth ratio (Vh/CrD) was 0.3 (range 0.04–3.4). Fifteen (83%) patients were TG2 antibody-positive and
16 (89%) were EmA-positive; the median TG2 and EmA levels were 60 (range 3.1–101) U/mL and 1:1000
(range 0–1:4000), respectively. Seven (39%) of the untreated coeliac disease patients were TG3-antibody
positive (median 7 AU/mL, range 0–189). As regards the 15 treated coeliac disease patients (median
age 48 (range 19–72) years, 4 males), the median Vh/CrD was 2.6 (range 2.1–3.1). Three subjects were
TG2 antibody-positive, and the median level in the group was 1.6 U/mL (range 0–26). Five subjects
had EmA, and the median titre was 0 (range 0–1:200). Four (27%) of the patients were TG3-antibody
positive (median 10 AU/mL, range 0–42).
In addition, seven patients investigated due to unspecific abdominal symptoms served as the
non-coeliac disease control group (median age 47 (range 24–76) years, 6 females) (Table 1). Coeliac
disease was excluded based on findings of normal small bowel mucosal histology and negative serum
TG2 antibodies and EmA.
All subjects gave their informed consent for inclusion before they participated in the study. The
study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved
by the Regional Ethics Committee of the Pirkanmaa Hospital District, Tampere, Finland (the ethic
approval codes are R16039, R03041, R04097 and R07122).
2.2. Serology
Serum IgA-class EmA was determined as previously described, with a dilution of 1:5 being
considered positive [23]. IgA-class TG2 and TG3 antibodies were detected using commercial
enzyme-linked immunosorbent assay kits (ELISA) (Celikey®, Phadia, Freiburg, Germany, and
anti-heTG IgA ELISA, Immunodiagnostik AG, Bensheim, Germany, respectively) as instructed by the
manufacturers. The cut o for positivity used in the present study was as instructed in the manuals,
namely 5 U/mL and >22 AU/mL for TG2 and TG3 antibodies, respectively.
2.3. Skin and Small Bowel Biopsies
Skin biopsies were taken from uninvolved elbow skin or perilesional skin when the rash was
present. The biopsies were fixed in optimal cutting temperature compound (OCT, Tissue-Tec, Miles
Inc. Elkhart, IN, USA), snap-frozen in liquid nitrogen, and stored at  70 C until analysed. Cutaneous
IgA deposits were detected in frozen sections by direct immunofluorescence staining using fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-IgA antibody (1:20, Dako A/S, Glostrup, Denmark). The
deposits were graded as negative (0), weak (1), moderate (2) or strong (3). The colocalization of the
dermal IgA with TG3 was demonstrated by double stainings with FITC-conjugated rabbit polyclonal
TG3 antibody (1:100) (A030, Zedira, Darmstadt, Germany) and tetramethylrhodamine-isothiocyanate
(TRITC)-conjugated goat anti-human IgA (1:50) (A18786, Life Technologies, Frederick, MD, USA).
Small intestinal biopsies were taken from the duodenum upon upper intestinal endoscopy. For
morphological studies, at least two biopsies were fixed in formalin, embedded in paran, and processed
for haematoxylin and eosin staining. The Vh/CrD was determined as previously described [24], with
a ratio of 2.0 being considered normal. For the detection of mucosal TG2-targeting IgA deposits,
1–2 biopsies were embedded in OCT and snap-frozen in liquid nitrogen. Sections were stained using
mouse monoclonal anti-TG2 antibody (CUB7402; NeoMarkers, Fremont, CA, USA) and FITC-labelled
rabbit anti-human IgA antibody (Dako A/S) as previously described [16]. The IgA deposits were
graded as negative (0), weak (1), moderate (2) or strong (3).
2.4. Detection of TG3- and TG2-Specific Plasma Cells
For the determination of intestinal TG3 and TG2 antibody-secreting plasma cells, small intestinal
biopsies were available from all 16 DH patients at pre-challenge and post-challenge, and from
all 18 untreated and 15 treated coeliac disease patients, as well as the seven non-coeliac control
subjects. Immunofluorescence staining of the plasma cells was performed using a technique previously
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described [19,21]. Briefly, 5 m-thick frozen sections of small intestinal biopsies were air-dried for 20
min at room temperature (RT), washed with phosphate-buered saline (PBS), and incubated with either
in-house biotinylated recombinant human TG2 (2 g/mL, T002, Zedira) or TG3 (5 g/mL, T024, Zedira)
in 1% bovine serum albumin-PBS (BSA-PBS) for 45 min at RT. Prior to staining, biotinylation of TG2
and TG3 was achieved with EZ-Link® Sulfo-NHS-LC-Biotin (Thermo Scientific, Waltham, MA, USA).
Thereafter, the sections were washed with PBS and incubated with TRITC-labelled streptavidin (1:1000,
Invitrogen, Camarillo, CA, USA) in 10% BSA-PBS for 30 min at RT. To distinguish the plasma cells,
sections were further incubated in the presence of mouse monoclonal anti-human CD138 antibody
(1:25, Bio-Rad Antibodies, Oxford, UK) in 1% BSA-PBS for 45 min at RT, followed by Alexa Fluor
488-conjugated anti-mouse antibody (1:2000, Invitrogen) in 1% BSA-PBS for 30 min at RT.
The slides were viewed with an Olympus BX60F5 (Olympus Finland Oy, Espoo, Finland)
microscope. The percentage of TG3- and TG2-specific plasma cells was determined by counting the
number of TG3- and TG2-specific plasma cells and the overall number of plasma cells in the entire
small bowel biopsy section by an independent evaluator guided by an expert consultant.
2.5. Statistics
The continuous variables are described with median values and ranges, and the categorized
values are presented as numbers and percentages. Statistical analyses were performed using the
Mann–Whitney U test, the Wilcoxon test, and Fisher’s exact test as appropriate. Spearman’s correlation
coecient was applied to assess correlations between dierent variables. A p-value < 0.05 was
considered statistically significant. The analyses were performed using IBM SPSS Statistics for
Windows (Version 23.0, IBM Corp., Armonk, NY, USA).
3. Results
3.1. General response to the gluten challenge in DH patients
After a median of four months (range 1–12 months) of gluten challenge, 12 out of the 16 DH patients
developed the DH rash. In addition, the number of patients with dermal TG3-IgA deposits increased
during the gluten challenge from 1 to 10. In parallel, the number of serum TG3 antibody-positive
DH patients increased from 4 (median level 4, range 0–41 AU/mL) to 14 (median level 140, range
5–190 AU/mL) (Table 2). At pre-challenge, none of the patients had circulating TG2 antibodies or
EmA, whereas at post-challenge, serum TG2 antibodies were present in 10 cases and EmA in 12 cases.
The median TG2 antibody level was 101 (range 0–101) U/mL and that of the EmA titre 1:500 (range
0–1:4000). During the challenge, the median Vh/CrD decreased from 2.6 (2.1–4.5) to 0.8 (range 0.1–3.1).
Intestinal TG2-IgA deposits were not detected in any of the DH patients at pre-challenge, but they
were present in 10 cases at post-challenge.
Table 2. Serological, skin, and small bowel mucosal biopsy findings in 16 gluten-challenged dermatitis
herpetiformis (DH) patients at pre- and post-challenge.
Pre-Challenge Post-Challenge
Positive Cases, n (%) Median (Range) Positive Cases, n (%) Median (Range)
Serum TG3 antibodies
(AU/mL) 4 (25) 4 (0–41) 14 (88) 140 (5–190)
Dermal TG3-IgA 1 (16) 0 (0–1) 10 (63) 1 (0–3)
Serum TG2 antibodies
(U/mL) 0 (0) 0 (0–0) 10 (63) 101 (0–101)
Serum EmA (titre) 0 (0) 0 (0–0) 12 (75) 1:500 (0–1:4000)
Intestinal TG2-IgA
deposits 0 (0) 0 (0–0) 10 (63) 1 (0–3)
Vh/CrD 2.6 (2.1–4.5) 0.8 (0.1–3.1)
The cut-o value for positivity was 5 U/mL for serum TG2 antibodies, 1:5 for serum EmA, and >22 AU/mL for
serum TG3 antibodies. The intensity of dermal TG3-IgA deposits and intestinal TG2-IgA deposits was graded from
negative (0) to strong positive (3). TG2: transglutaminase 2; EmA: endomysial antibodies; Vh/CrD: villous height
crypt depth ratio; TG3: transglutaminase 3; IgA: immunoglobulin A.
Nutrients 2020, 12, 467 5 of 10
3.2. TG3-specific plasma cell responses
At pre-challenge, intestinal TG3 antibody-secreting plasma cells were detected in 2 out of 16
biopsy samples taken from DH patients (Figure 1A). The median percentage of such cells out of all
lamina propria plasma cells in the whole pre-challenge group was 0 (range 0–1.2%). At post-challenge,
these cells were found in 9 of the 16 DH patient mucosal specimens, and the median percentage in the
group was 1.4 (range 0%–10.9%) (Figure 1A). To address the putative TG2-cross-reactivity of the TG3
antibodies secreted by the plasma cells, we preincubated the sections with unlabelled recombinant TG2
prior to biotinylated TG3 and found that the number of TG3 antibody-secreting cells was not reduced
(data not shown). Regardless of the presence or absence of serum TG3 antibodies, neither the untreated
coeliac disease patients nor the non-coeliac control subjects had intestinal TG3 antibody-secreting
plasma cells, but they were present in one treated coeliac disease patient (1.9% of all lamina propria
plasma cells).
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such plasma cells, three had circulating TG3 antibodies (23, 40, and 41 AU/mL). At post-challenge, 
regardless of the presence or absence of intestinal TG3 antibody-secreting plasma cells, all DH 
patients except two TG3 plasma cell-negative subjects had serum TG3 antibodies. The DH patients 
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(range 5–190), respectively, p = 0.023)). A correlation between the percentage of intestinal TG3 
Figure 1. The percentage of transglutaminase (TG) 3- (A) and TG2-specific plasma cells (B) of all
intestinal plasma cells in dermatitis herpetiformis patients at pre- and post-challenge. The grey area
represents the absence of plasma cells. The black circles in A indicate negativity for serum TG3
antibodies and in B for both endomysial and TG2 antibodies, while the white circles indicate positivity.
The grey circle in B indicates one individual with positive EmA but missing data for TG2 autoantibodies.
Representative immunofluorescent pictures showing specific plasma cells (indicated with arrows) are
shown on the right. The colour yellow indicates the colocalization of recombinant TG3 or TG2 (red) with
plasma cell marker CD138 (green). Scale bar = 100 m. A p-value < 0.05 was considered significant.
Of the two DH patients with intestinal TG3 antibody-secreting plasma cells at pre-challenge, one
was serum TG3 antibody-positive (30 AU/mL) (Figure 1A), whereas among the 14 patients without
such plasma cells, three had circulating TG3 antibodies (23, 40, and 41 AU/mL). At post-challenge,
regardless of the presence or absence of intestinal TG3 antibody-secreting plasma cells, all DH patients
except two TG3 plasma cell-negative subjects had serum TG3 antibodies. The DH patients with TG3
antibody-secreting plasma cells at post-challenge had significantly higher circulating TG3 antibody
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levels than those without such cells (median 190 AU/mL (range 24–190) vs. 30 AU/mL (range 5–190),
respectively, p = 0.023)). A correlation between the percentage of intestinal TG3 antibody-secreting
plasma cells and serum TG3 antibody levels was detected (Rs = 0.541, p = 0.030) (Table 3).
Table 3. Correlations between the percentages of intestinal transglutaminase (TG) 3- and 2-specific
plasma cells and relevant serum, skin, and small bowel mucosal findings in dermatitis herpetiformis
(DH) patients at post-challenge. RS, Spearman correlation coecient. A p-value < 0.05 was
considered significant.
RS p-Value
TG3-specific plasma cells
Serum TG3 antibodies 0.541 0.030
Intensity of dermal TG3-IgA 0.175 0.517
Vh/CrD  0.273 0.307
TG2-specific plasma cells
Serum TG2 antibodies 0.759 0.001
Serum EmA 0.732 0.001
Intensity of intestinal TG2-IgA deposits 0.691 0.003
Vh/CrD  0.195 0.469
TG3: transglutaminase 3; IgA: immunoglobulin A; Vh/CrD: villous height crypt depth ratio; TG2: transglutaminase
2; EmA: endomysial antibodies.
All 9 DH patients with intestinal TG3 antibody-secreting plasma cells at post-challenge had skin
symptoms compatible with DH, and seven of these had dermal TG3-IgA deposits. Of the seven
patients without such plasma cells, three presented with the DH rash and dermal TG3-IgA deposits in
the post-challenge examination. The intensity of the dermal TG3-IgA deposits and Vh/CrD did not
dier statistically between the TG3 antibody-secreting plasma cell-positive and -negative DH patients
at post-challenge, nor did they correlate with the percentage of intestinal TG3 antibody-secreting
plasma cells (Table 3).
3.3. TG2-specific plasma cell responses
Intestinal TG2 antibody-secreting plasma cells were present in two DH patients at pre-challenge,
and both were TG2-seronegative. The median percentage of TG2 antibody-secreting plasma cells in
the whole group at pre-challenge was 0 (range 0%–0.9%) (Figure 1B). At post-challenge, 12 of the 16
DH patients had such plasma cells in the duodenal samples, and the median percentage of the cells
had increased to 1.2 (range 0%–12.6%) (Figure 1B). In the coeliac disease control group, 17 of the 18
untreated patients had TG2 antibody-secreting plasma cells (median 4.2%, range 0%–20.0%), while
such cells were found in 13 of the 15 treated coeliac patients (median 1.1%, range 0–4.6). Only one of
the seven non-coeliac controls patients had intestinal TG2 antibody-secreting plasma cells (0.4% of all
intestinal plasma cells).
Of the 12 DH patients with TG2 antibody-secreting plasma cells at post-challenge, 9 had TG2
antibodies in the serum, 11 had EmA in the serum, and 10 presented with intestinal TG2-IgA deposits.
Of the four patients without TG2 antibody-secreting plasma cells, one had both TG2 and EmA, but
none had TG2-IgA deposits in the small bowel mucosa. The patients with TG2 antibody-secreting
plasma cells at post-challenge had significantly higher circulating TG2 antibody levels (median 101
U/mL (range 0–101) vs. 0 U/mL (range 0–9.5), p = 0.010)) and EmA (median 1:500 (range 0–1:4000)
vs. 0 (range 0–1:200), p = 0.013)), as well as more intense intestinal TG2-IgA deposits (median 1.5
(range 0–3) vs. 0 (0 range), p = 0.013)) compared to the plasma cell-negative patients. Vh/CrD was
comparable between the groups (median 0.8 (range 0.1–2.5) vs. median 0.8 (range 0.7–3.1), p = 0.862)).
The percentage of intestinal TG2 antibody-secreting plasma cells correlated with the levels of serum
TG2 antibodies (Rs = 0.759, p = 0.001) and EmA (Rs = 0.732, p = 0.001) as well as the intensity of the
intestinal TG2 deposits (Rs = 0.691, p = 0.003), but not with Vh/CrD (Table 3).
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4. Discussion
The current study confirms the presence of TG3 antibody-secreting plasma cells in the small
intestinal lamina propria of DH patients [22]. Moreover, according to the current study—and also
our previous study [22]—such cells can only be detected in single coeliac patients, pointing to the
specificity of this cell population for DH. In addition, our data shows that in long-term treated DH
patients in clinical remission, both the intestinal TG3 and TG2 antibody-secreting plasma cells are
mostly absent, but in more than half of the patients the cells appear after a gluten challenge of up to
one year. Therefore, the study is the first to address the dynamics of these cell populations during
gluten reintroduction in DH.
According to our results, during a median of four months of gluten challenge, the percentage of
TG3 and TG2 antibody-secreting plasma cells of all lamina propria plasma cells increased significantly.
Although these plasma cell populations were not detected in all DH patients with a clear gluten-induced
disease relapse, the findings strongly point to the gluten-dependency of these cells. In this regard, our
results are in line with the previously reported gluten responsiveness of TG2-specific plasma cells
in coeliac disease [19,21]. Earlier studies have reported TG2 antibody-secreting cells in all untreated
coeliac disease patients with median values above 4% [19–21]. In addition, such intestinal TG2
antibody-secreting cells with median values around 2% have been described in a subset of early-phase
coeliac disease patients with positive serum TG2-targeted antibodies but normal small bowel mucosal
morphology [21]. Thus, the percentage of both TG2 and TG3 antibody-secreting plasma cells in DH
patients after a gluten challenge in the current study is more comparable to early-phase coeliac disease
rather than untreated coeliac disease. This fits well with the fact that small bowel mucosal damage
in DH is often milder than in coeliac disease, and thus DH is often considered to represent incipient
coeliac disease [25]. In the current study, the fairly short gluten exposure might have had an eect of
the number of patients with the intestinal plasma cell subsets as well as the percentage of such cells,
and a longer gluten intake might be required for all DH patients to react to a similar extent as in overt
coeliac disease.
In the current study, the percentage of both intestinal TG3- and TG2-specific plasma cells at
post-challenge correlated with the corresponding serum autoantibody levels in DH. This finding
seems to contrast with the previously reported lack of correlation between the frequency of intestinal
TG2 antibody cells with serum TG2 antibody levels in untreated coeliac disease [19,21,26]. However,
the earlier reported data and our current results are not directly comparable; they are derived from
dierent disease manifestations, and our new finding in DH patients represents the scenario of a rather
unique reactivation of the gluten-induced immune response within a comparably short period. Among
our cohort of DH patients, there were also TG3- and TG2-seropositive subjects without corresponding
plasma cells in the intestine. This might reflect the fact that one biopsy might be unrepresentative
for the duodenum and the whole small intestine as the mucosal lesion can be patchy or aect only
certain parts of the bowel. Recently, the molecular composition of serum and intestinally produced
TG2 antibodies have been shown to dier, suggesting that TG2 antibody-secreting plasma cells are at
least not the sole source of corresponding serum autoantibodies [27]. Thus, our results that at subject
level, the presence of intestinal TG3- and TG2-specific plasma cells did not always coincide with the
serum antibodies could be explained by either of the two above mentioned scenarios.
Two distinct populations of TG3 antibodies have been suggested to exist: one targeting TG3
specifically and detected in only DH, and another recognizing both TG3 and TG2 that is present
in both DH and coeliac disease patients [1]. Our results show that the number of intestinal TG3
antibody-secreting plasma cells was not reduced in DH patients by preincubation with recombinant
TG2, suggesting that plasma cells secreting TG3-specific antibodies which are not cross-reactive with
TG2 are present in the intestinal mucosa, and thus this fits well with the concept of DH patients having
TG3-specific antibodies. On the other hand, we did not detect recombinant TG3-binding cells in the
intestinal mucosa in the majority of coeliac patients—even those with serum TG3 antibodies—a finding
congruent with earlier results demonstrating the lack of cross-reactivity of coeliac patient intestinal TG2
Nutrients 2020, 12, 467 8 of 10
antibodies with TG3 [28]. Based on this, it appears that the intestinal TG3 antibody-secreting plasma
cells are specific to DH. However, it must be noted that an immunofluorescence method might not
be optimal for detecting cross-reactive antibody populations and thus more investigations regarding
coeliac disease patient TG3 antibody-secreting cells as well as the origin of serum TG3 antibodies are
needed. Despite their specificity for DH, according to our results some patients at post-challenge had
clinical and/or immunological skin findings in the absence of intestinal TG3 antibody-secreting plasma
cells. This implies that the TG3 autoantibodies produced specifically by intestinal plasma cells are
neither invariably related to the presence of dermal IgA deposits, as previously implicated [29,30], nor
to the appearance of cutaneous symptoms.
The strength of the current study is the well-defined cohort of long-term-treated DH patients
followed-up prospectively for up to one year during a gluten-challenge. This design allowed us to
investigate the dynamics of the plasma cells secreting TG3 and TG2 autoantibodies and to compare
them to several other disease parameters in DH. It must be noted, however, that our findings might
not be applicable to DH at the time of diagnosis, when the patients are likely to have ingested gluten
for a considerably longer period. A further limitation is the relatively small number of serum TG3
antibody-positive coeliac disease patients, which hampers the drawing of definitive conclusions about
this particular group. However, as only around 30% of coeliac patients are reported to have circulating
TG3 autoantibodies [3], we consider our coeliac patients representative. Moreover, the untreated and
one-year-treated coeliac disease patients are not directly comparable to the DH patients undergoing a
gluten challenge.
5. Conclusions
The current study verifies for the first time that intestinal TG3 and TG2 antibody-secreting plasma
cells are gluten-responsive in DH. Moreover, the percentage of both plasma cell subsets correlates
with the levels of corresponding serum antibodies in DH patients after a gluten challenge, but the
presence of plasma cells and serum antibodies does not always coincide at the individual patient
level. Furthermore, the absence of intestinal TG3 antibody-secreting plasma cells in coeliac patients,
even those with serum TG3 antibodies, points to the specificity of these cells for DH. Regardless of
this disease specificity, their connection with other disease parameters, including skin symptoms and
dermal IgA deposits, is weak, and therefore further studies on their significance in DH are needed.
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